X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
AMI-918, an allogeneic, off-the-shelf investigational cell therapy aimed at providing functional liver support in the acute setting, is an important advancement in transforming the treatment of severe liver disease.
Lead Product(s): AMI-918
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: AMI-918
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 09, 2022
Details:
The proceeds from this financing will enable the continued expansion of Ambys’s proprietary liver cell therapy production capabilities and the advancement of the company’s lead program, AMI-918, through pre-IND activities.
Lead Product(s): Allogenic Liver-cell Therapy
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: AMI-918
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Third Rock Ventures
Deal Size: $47.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing December 21, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
